Catalent CEO to remain in charge of contract drugmaker after Novo Holdings’ buyout
(Reuters) – Catalent CEO Alessandro Maselli said on Monday he will remain at the helm of the U.S.-based contract drugmaker after it is acquired by Novo Holdings, the controlling shareholder of weight-loss drug manufacturer Novo Nordisk. Maselli’s open letter comes on the back of criticism over Novo Holding’s $16.5-billion acquisition of Catalent, which U.S. consumer …
Catalent CEO to remain in charge of contract drugmaker after Novo Holdings’ buyout Read More »









